What it's for (Indications)
- Floctafenine, historically marketed under brand names such as Idarac, was primarily indicated for the symptomatic treatment of acute pain of various etiologies.
- This included, but was not limited to, pain associated with musculoskeletal disorders (e.
- g.
- , sprains, strains), post-operative pain, dental pain, and dysmenorrhea.
- As a non-steroidal anti-inflammatory drug (NSAID) of the anthranilic acid derivative class, its therapeutic utility was focused on providing effective short-term relief from mild to moderate pain.
- It was intended for situations requiring rapid analgesic and anti-inflammatory action to improve patient comfort and functionality.
- However, due to significant safety concerns, particularly severe hypersensitivity reactions, its availability has been significantly restricted or withdrawn from many global markets, reflecting a cautious stance on its clinical utility in contemporary practice.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Historically, the recommended dosage for floctafenine in adult patients was typically 200 mg to 400 mg, administered orally, two to three times daily. The maximum recommended daily dose generally did not exceed 1200 mg. Dosage regimens were always to be tailored to the individual patient's response and tolerance, with the lowest effective dose used for the shortest possible duration to manage acute pain, consistent with general NSAID prescribing principles. It was advised to take the medication with food or milk to minimize potential gastrointestinal irritation. Dosage adjustments were considered necessary in specific patient populations, such as the elderly or those with mild to moderate renal impairment, although its use in these groups was often approached with extreme caution due to an increased risk of adverse effects, including serious renal events and hypersensitivity. |
Safety & Warnings
Common Side Effects
- Floctafenine, like other non-steroidal anti-inflammatory drugs (NSAIDs), was associated with a range of side effects affecting various organ systems.
- Common adverse reactions included gastrointestinal disturbances such as nausea, vomiting, dyspepsia, abdominal pain, diarrhea, and constipation, with a risk of more serious events like gastrointestinal ulceration, bleeding, or perforation.
- Central nervous system effects could manifest as headache, dizziness, somnolence, or insomnia.
- Dermatological reactions like rashes, pruritus, and urticaria were also observed.
- However, the most critical and severe adverse effects, which ultimately led to the drug's withdrawal from many markets, were severe hypersensitivity reactions.
- These included anaphylactic shock, angioedema, and bronchospasm, often occurring unpredictably and sometimes fatally.
- Acute renal failure, interstitial nephritis, and other forms of nephrotoxicity were significant concerns.
- Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) were also reported, further contributing to its unfavorable safety profile.
- Cardiovascular effects like hypertension and edema were also noted, consistent with the NSAID class.
Serious Warnings
- Black Box Warning: None
- The use of floctafenine necessitates stringent adherence to warnings and contraindications due to its significant risk profile.
- It was absolutely contraindicated in patients with known hypersensitivity to floctafenine, other NSAIDs, or salicylates.
- A history of asthma, rhinitis, or urticaria precipitated by NSAIDs represented a contraindication due to the risk of cross-reactivity and severe allergic reactions.
- Other contraindications included active peptic ulcer disease, gastrointestinal bleeding, severe renal or hepatic impairment, severe heart failure, and during the third trimester of pregnancy due to potential fetal harm and complications during labor.
- A paramount warning associated with floctafenine is the high risk of severe, potentially fatal, hypersensitivity reactions, including anaphylactic shock, angioedema, and severe cutaneous adverse reactions (SCARs).
- These reactions could occur upon first exposure or re-exposure, sometimes with delayed onset, and were a primary driver for the drug's market withdrawal.
- Patients should be meticulously screened for any history of allergic reactions to NSAIDs.
- Furthermore, the risk of acute renal failure, particularly in dehydrated or elderly patients, and those with pre-existing renal compromise, was a significant concern.
- Concomitant use with anticoagulants, methotrexate, lithium, or certain diuretics required extreme caution due to pharmacokinetic interactions and increased toxicity risks.
- Given its withdrawal from many markets due to these severe safety concerns, floctafenine is generally not recommended for use and is largely unavailable.
How it Works (Mechanism of Action)
Floctafenine functions as a non-steroidal anti-inflammatory drug (NSAID) primarily through the inhibition of cyclooxygenase (COX) enzymes. It is considered a prodrug, meaning it is pharmacologically inactive in its administered form. Following oral administration, floctafenine undergoes rapid metabolism in the body, primarily through hydrolysis, to its active metabolite, floctafenic acid. This active metabolite is responsible for the therapeutic effects. Floctafenic acid exerts its analgesic, anti-inflammatory, and antipyretic effects by non-selectively inhibiting both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoforms. COX enzymes are crucial for the biosynthesis of prostaglandins, thromboxanes, and prostacyclins from arachidonic acid. Prostaglandins, in particular, play pivotal roles in mediating pain, inflammation, and fever. By blocking their synthesis, floctafenic acid effectively reduces the inflammatory response and perception of pain. While its inhibition is generally non-selective, like many older NSAIDs, this mechanism underpins both its therapeutic benefits and some of its common side effects, such as gastrointestinal irritation due to COX-1 inhibition in the gastric mucosa.
Commercial Brands (Alternatives)
No other brands found for this formula.